Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When a study describing a large outlying prevalence of 14.0% in Indian patients with CRC42 was removed from the analysis, the median prevalence was 2.3% (0.7% to 6.9%).”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [42]
In the citing paper
“7.0% in JAPAC (range, 1.9% to 32.8%), although this was reduced to 6.5% (range, 1.9% to 21.2%) when a study with a large outlier prevalence42 was excluded”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu464 · Cited by 108
Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.
(2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8886 · Cited by 106
Research works printed but not linked: 46
- Ferlay, 2015, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, E359
- Sung, 2005, Increasing incidence of colorectal cancer in Asia: Implications for screening, Lancet Oncol, 871
- Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 69
- Mateka, 2013, Interesting trends in incidence and mortality rates of colorectal cancer in the United States of America, J Gastrointest Dig Syst, 004
- Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 759
- Ciardiello, 2003, Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs, Eur J Cancer, 1348
- Shields, 2000, Understanding Ras: 'It ain't over 'til it's over', Trends Cell Biol, 147
- Traxler, 2001, Tyrosine kinase inhibitors: From rational design to clinical trials, Med Res Rev, 499
- Lièvre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 3992
- Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 1626
- Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, SchramaJG. et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). In: Program and abstracts of the 44rd American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract LBA4011. · DOI · Paper page
- Hecht JR, Mitchell E, Chidiac T, Carroll Scroggin, Christopher Hagenstad, David Spigel, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/-panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized controlled trial (PACCE). In: Program and abstracts of the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 273.
- Jimeno, 2009, KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection, J Clin Oncol, 1130
- Bos, 1989, Ras oncogenes in human cancer: A review, Cancer Res, 4682
- De, 2008, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.Ann Oncol, 508
- Kressner, 1998, Ki-ras mutations and prognosis in colorectal cancer, Eur J Cancer, 518
- Riely, 2008, KRAS mutations: An old oncogene becomes a new predictive biomarker, J Mol Diagn, 493
- Breivik, 1994, K-ras mutation in colorectal cancer: Relations to patient age, sex and tumour location, Br J Cancer, 367
- Shen, 2011, Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients, World J Gastroenterol, 809
- Sammoud, 2012, Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia, Appl Immunohistochem Mol Morphol, 146
- Wu, 2005, Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan, Cancer Genet Cytogenet, 55
- Okulczyk, 2003, Evaluation of K-RAS gene in colorectal cancer, Folia Histochem Cytobiol, 97
- Breivik, 1997, Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors, Int J Cancer, 664
- Phang, 1995, K-ras mutation in colorectal carcinomas from singapore, Int J Oncol, 191
- Sorich, 2015, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials, Ann Oncol, 13
- Stein, 2014, How to select the optimal treatment for first line metastatic colorectal cancer, World J Gastroenterol, 899
- Slattery, 2000, Associations between dietary intake and Ki-ras mutations in colon tumors: A population-based study, Cancer Res, 6935
- (A) Ries L AG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2005. Bethesda, MD: 2008. (B) Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004 1;101 (1):3-27. (C) http://seer.cancer.gov/statfacts/html/colorect.html. · DOI · Paper page
- Angulo, 2010, A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma, J Mol Diagn, 292
- Whitehall, 2009, A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting, J Mol Diagn, 543
- Sahoo, 2011, Screening for EGFR mutations in lung cancer, a report from India, Lung Cancer, 316
- Al-Allawi, 2012, The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma, Indian J Cancer, 163
- Samowitz, 2000, Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study, Cancer Epidemiol Biomarkers Prev, 1193
- Elnatan, 1996, C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas, Eur J Cancer, 491
- Einspahr, 2006, Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics, Cancer Epidemiol Biomarkers Prev, 1443
- Baskin Y, Dagdeviren YK, Calibasi G, Canda AE, Sarioglu S, Ellidokuz H, Oztop I. KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas. J Gastrointest Oncol. 2014 Aug;5(4):265-9
- Parkin DM, Whelan SL, Ferlay L, Young RJ. Cancer Incidence in Five Continents (IARC Sci. Publ. No. 143) Series. Vol. 143. Lyon: International Agency for Research on Cancer; 1997. p. 566-7.
- Scott, 2014, KRAS mutation testing of metastatic colorectal cancer in Australia: Where are we at?, Asia Pac J Clin Oncol, 261
- Nakanishi, 2013, Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer, Int J Clin Oncol, 1042
- Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers, Br J Cancer, 1757
- Díaz-Rubio, 2012, Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: A TTD group cooperative study, PLoS One, e47345
- Brink, 2003, K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study, Carcinogenesis, 703
- Zhu, 2012, KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese, Zhonghua Bing Li Xue Za Zhi, 584
- Bisht, 2014, Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: Determination of frequency, distribution pattern in Indian colorectal carcinoma, Med Oncol, 124
- Sameer, 2009, Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: A report, Indian J Cancer, 219
- Sinha, 2013, Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: Indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population, PLoS One, e60142
Cited by
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Metadata
- Authors
- Veldore, V., Rao, M., Prabhudesai, S., Tejaswi, R., Kakara, S., Pattanayak, S., Krishnamoorthy, N., Tejaswini, B., Hazarika, D., Gangoli, A., Rahman, S., Dixit, J., Naik, R., Diwakar, R., Satheesh, C., Shashidhara, H., Patil, S., Gopinath, K., & Kumar, B.
- Venue
- Indian Journal of Cancer
- Published
- 2014
- Volume
- 51
- Issue
- 4
- Pages
- 531
- ISSN
- 0019-509X
- Cited by
- 9
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. https://app.cochat.ai/papers/10.4103/0019-509x.175371
- The paper
- Veldore, V., Rao, M., Prabhudesai, S., Tejaswi, R., Kakara, S., Pattanayak, S., Krishnamoorthy, N., Tejaswini, B., Hazarika, D., Gangoli, A., Rahman, S., Dixit, J., Naik, R., Diwakar, R., Satheesh, C., Shashidhara, H., Patil, S., Gopinath, K., & Kumar, B. (2014). Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. Indian Journal of Cancer. https://doi.org/10.4103/0019-509x.175371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.